Stay updated on Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Sign up to get notified when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.

Latest updates to the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, indicating a minor site version update. This change reflects maintenance of the page version rather than any modification to trial content or functionality.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous v3.6.2. This reflects a minor maintenance update to the page without changes to the study information or its presentation.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page's revision tag is updated to v3.6.2, reflecting a new version. The previous v3.6.0 tag was removed.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page now displays the recruitment status 'No longer looking for participants' and adds new help/navigation sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study'). The 'Intervention / Treatment' label has been updated to 'Intervention/Treatment' and the revision tag updated to v3.6.0.SummaryDifference0.5%

- Check61 days agoChange DetectedThe revision indicator on the page updated from v3.5.4 to v3.5.5, signaling a minor update to the version history rather than a change to study content.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page revision metadata was updated from v3.5.3 to v3.5.4, indicating a newer version of the page. This change reflects a backend update rather than a user-facing modification.SummaryDifference0.1%

Stay in the know with updates to Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fostamatinib and Ruxolitinib in Myelofibrosis Clinical Trial page.